Clinical Trial Update: Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating SRP-9004 for limb girdle muscular dystrophy type 2D/R3 has been terminated; the update concerns safety, tolerability, and potential e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limb Girdle Muscular Dystrophy
• Limb-girdle Muscular Dystrophy Type 2d

Drugs mentioned

• SRP-9004

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type 2D/R3 | Phase 1 | Status: TERMINATED